Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $42.5 million.

  • Standard Biotools' Current Deferred Revenue fell 789.5% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year decrease of 789.5%. This contributed to the annual value of $42.9 million for FY2024, which is 18391.62% up from last year.
  • Latest data reveals that Standard Biotools reported Current Deferred Revenue of $42.5 million as of Q3 2025, which was down 789.5% from $43.0 million recorded in Q2 2025.
  • Standard Biotools' 5-year Current Deferred Revenue high stood at $48.5 million for Q2 2024, and its period low was $14.6 million during Q4 2022.
  • Moreover, its 5-year median value for Current Deferred Revenue was $18.9 million (2021), whereas its average is $27.4 million.
  • As far as peak fluctuations go, Standard Biotools' Current Deferred Revenue plummeted by 1951.22% in 2022, and later skyrocketed by 21372.79% in 2024.
  • Quarter analysis of 5 years shows Standard Biotools' Current Deferred Revenue stood at $17.9 million in 2021, then dropped by 18.45% to $14.6 million in 2022, then grew by 3.55% to $15.1 million in 2023, then surged by 183.92% to $42.9 million in 2024, then dropped by 1.1% to $42.5 million in 2025.
  • Its Current Deferred Revenue was $42.5 million in Q3 2025, compared to $43.0 million in Q2 2025 and $45.3 million in Q1 2025.